Daphne D. Williams

发表

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

Suzanne F. Jones, H. Burris, S. Boerner, 2011, Investigational New Drugs.

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

J. Wolchok, S. Chasalow, S. O’Day, 2013, Cancer immunity.

Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia

D. Ouellet, P. Mudd, B. Johnson, 2013, Cancer Chemotherapy and Pharmacology.

Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects

B. Peng, C. Bowen, P. Gorycki, 2011, Drug Metabolism and Disposition.

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.

E. Lee, B. Peng, A. Allred, 2011, British journal of clinical pharmacology.

Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic Purpura

D. Ouellet, Daphne D Williams, E. Gibiansky, 2011, Journal of clinical pharmacology.

Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics

B. Peng, Daphne D Williams, J. Bauman, 2011, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers

B. Peng, C. Bowen, J. Park, 2011, Journal of clinical pharmacology.

Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.

B. Peng, C. Bowen, J. Park, 2010, British journal of clinical pharmacology.

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.

B. Peng, Daphne D Williams, Yanli Deng, 2009, Clinical therapeutics.

Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator

Sean Zhang, Daphne D Williams, E. Masson, 2016, British journal of clinical pharmacology.

Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans

V. Arora, A. Allentoff, J. Gan, 2011, Drug Metabolism and Disposition.

Metabolism and Disposition of [ 14 C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans □ S

V. Arora, A. Allentoff, J. Gan, 2011 .

A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors

R. Schilsky, M. Ratain, M. Russo, 2004, Clinical Cancer Research.

Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors

T. Mekhail, R. Ganapathi, J. Gan, 2010, Drug Metabolism and Disposition.

A Phase I Study To Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Oral Platelet Growth Factor (SB-559448) in Healthy Subjects.

B. Peng, S. Su, J. Park, 2006 .

Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

M. Carleton, E. Jaffee, C. Drake, 2018 .

Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology

Yuan-qing Xia, M. Jemal, J. Gan, 2012, Drug Metabolism and Disposition.